Francois Nader - Apr 28, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Apr 28, 2022
Transactions value $
$0
Form type
4
Date filed
5/2/2022, 04:40 PM
Previous filing
Dec 16, 2021
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $0 +703 $0.00 703 Apr 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -703 -100% $0.00* 0 Apr 28, 2022 Common Stock 703 $0.00 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Award $0 +5.42K $0.00 5.42K Apr 28, 2022 Common Stock 5.42K $142.52 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The shares subject to this restricted stock unit award vested in full on April 28, 2022.
F3 This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.